Phillip John Birch

Title: The Innovations of Phillip John Birch

Introduction

Phillip John Birch is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of pharmaceuticals, particularly in pain management. His innovative work has led to the development of a unique formulation that enhances the delivery of buprenorphine.

Latest Patents

Phillip John Birch holds a patent for "Buprenorphine formulations for intranasal delivery." This patent describes aqueous formulations suitable for intranasal administration that comprise buprenorphine or a physiologically acceptable salt or ester thereof. The formulations include a pectin with a degree of esterification of less than 50%, chitosan, and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or hydroxypropylmethylcellulose. These formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or its salt or ester can achieve a therapeutic plasma concentration of 0.2 ng/ml or greater within 30 minutes, maintaining this level for at least 2 hours.

Career Highlights

Throughout his career, Phillip John Birch has worked with various companies, including Vernalis Limited and Archimedes Development Limited. His experience in research and development has been instrumental in advancing pharmaceutical formulations.

Collaborations

Phillip has collaborated with notable individuals in his field, including Ann Gail Hayes and Peter James Watts. Their combined expertise has contributed to the success of his innovative projects.

Conclusion

Phillip John Birch's contributions to the field of pharmaceuticals, particularly through his patent for buprenorphine formulations, highlight his role as an influential inventor. His work continues to impact pain management therapies positively.